Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Prior malignancy impact on survival outcomes of glioblastoma multiforme; population-based study.

Al-Husseini MJ, Saad AM, El-Shewy KM, Nissan NE, Gad MM, Alzuabi MA, Alfaar AS.

Int J Neurosci. 2018 Oct 26:1-23. doi: 10.1080/00207454.2018.1538989. [Epub ahead of print]

PMID:
30366515
2.

Impact of Prior Malignancy on Survival Outcomes of Stage IV Pancreatic Adenocarcinoma: SEER-Based Cohort.

Al-Husseini MJ, Saad AM, Turk T, Tabash MA, Abdel-Rahman O.

J Gastrointest Cancer. 2018 Aug 14. doi: 10.1007/s12029-018-0158-4. [Epub ahead of print]

PMID:
30105523
3.

Impact of prior malignancy on outcomes of stage IV esophageal carcinoma: SEER based study.

Saad AM, Al-Husseini MJ, Elgebaly A, Aboshady OA, Salahia S, Abdel-Rahman O.

Expert Rev Gastroenterol Hepatol. 2018 Apr;12(4):417-423. doi: 10.1080/17474124.2018.1426458. Epub 2018 Jan 16.

PMID:
29316808
4.

Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis.

Thumma SR, Fairbanks RK, Lamoreaux WT, Mackay AR, Demakas JJ, Cooke BS, Elaimy AL, Hanson PW, Lee CM.

World J Surg Oncol. 2012 May 3;10:75. doi: 10.1186/1477-7819-10-75.

5.

Impact of gender on the survival of patients with glioblastoma.

Tian M, Ma W, Chen Y, Yu Y, Zhu D, Shi J, Zhang Y.

Biosci Rep. 2018 Nov 7;38(6). pii: BSR20180752. doi: 10.1042/BSR20180752. Print 2018 Dec 21.

6.

Influence of insurance status on survival of adults with glioblastoma multiforme: A population-based study.

Rong X, Yang W, Garzon-Muvdi T, Caplan JM, Hui X, Lim M, Huang J.

Cancer. 2016 Oct 15;122(20):3157-3165. doi: 10.1002/cncr.30160. Epub 2016 Aug 8.

7.

Prior malignancies in patients harboring glioblastoma: an institutional case-study of 2164 patients.

Zacharia BE, DiStefano N, Mader MM, Chohan MO, Ogilvie S, Brennan C, Gutin P, Tabar V.

J Neurooncol. 2017 Sep;134(2):245-251. doi: 10.1007/s11060-017-2512-y. Epub 2017 May 27. Review.

PMID:
28551847
8.

Risk of subsequent cancer among pediatric, adult and elderly patients following a primary diagnosis of glioblastoma multiforme: a population-based study of the SEER database.

Li X, Li Y, Cao Y, Li P, Liang B, Sun J, Feng E.

Int J Neurosci. 2017 Nov;127(11):1005-1011. doi: 10.1080/00207454.2017.1288624. Epub 2017 Mar 17.

PMID:
28288541
9.

Effect of marital status on survival in glioblastoma multiforme by demographics, education, economic factors, and insurance status.

Xie JC, Yang S, Liu XY, Zhao YX.

Cancer Med. 2018 Aug;7(8):3722-3742. doi: 10.1002/cam4.1688. Epub 2018 Jul 15.

10.
11.

Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis.

Kozak KR, Moody JS.

Neuro Oncol. 2009 Dec;11(6):833-41. doi: 10.1215/15228517-2008-123.

12.

Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries.

Darefsky AS, King JT Jr, Dubrow R.

Cancer. 2012 Apr 15;118(8):2163-72. doi: 10.1002/cncr.26494. Epub 2011 Aug 31.

13.

Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.

Niranjan A, Kano H, Iyer A, Kondziolka D, Flickinger JC, Lunsford LD.

J Neurosurg. 2015 Apr;122(4):757-65. doi: 10.3171/2014.11.JNS13295. Epub 2015 Jan 16.

PMID:
25594327
14.

Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma.

Barnholtz-Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, Sloan AE.

J Neurosurg. 2008 Apr;108(4):642-8. doi: 10.3171/JNS/2008/108/4/0642.

PMID:
18377240
15.

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.

Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA.

Neuro Oncol. 2007 Jan;9(1):29-38. Epub 2006 Nov 15.

16.

Variation in management of spinal gliobastoma multiforme: results from a national cancer registry.

Moinuddin FM, Alvi MA, Kerezoudis P, Wahood W, Meyer J, Lachance DH, Bydon M.

J Neurooncol. 2018 Nov 20. doi: 10.1007/s11060-018-03054-2. [Epub ahead of print]

PMID:
30460627
17.

Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).

Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N.

Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13. doi: 10.1053/j.seminoncol.2014.09.010. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e33-43.

18.

Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome.

Kozak KR, Mahadevan A, Moody JS.

Neuro Oncol. 2009 Apr;11(2):183-91. doi: 10.1215/15228517-2008-076. Epub 2008 Sep 9.

19.

National Trends for Reoperation in Older Patients with Glioblastoma.

Chen YR, Sole J, Ugiliweneza B, Johnson E, Burton E, Woo SY, Koutourousiou M, Williams B, Boakye M, Skirboll S.

World Neurosurg. 2018 May;113:e179-e189. doi: 10.1016/j.wneu.2018.01.211. Epub 2018 Feb 7.

PMID:
29427817
20.

Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.

Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE.

J Natl Cancer Inst. 2015 Feb 9;107(4). pii: djv002. doi: 10.1093/jnci/djv002. Print 2015 Apr.

Supplemental Content

Support Center